Oral Contraceptive Use and Benign Gynecologic Conditions

F Chiaffarino, Francesça Chiaffarino, Fabio Parazzini, F Parazzini, Carlo La Vecchia, C La Vecchia, E Ricci, Elena Ricci, Crosignani PG, P. G. Crosignani, Pier Giorgio Crosignani
Contraception · 1998 · vol. 57(1) , pp. 11–18 · doi:10.1016/s0010-7824(97)00201-1 · PMID:9554245 · W1973557514
review OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper investigates the association between oral contraceptive use and the incidence of benign gynecologic conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The following review considers the main epidemiologic data on oral contraceptives (OC) and the risk of major benign gynecologic diseases. Earlier studies investigating the relationship between OC use and functional ovarian cysts indicated that the use of high-dose combination OC have a protective effect, whereas low-dose monophasic or multiphasic pills have little or no effect. With regard to seromucinous cysts, the scanty data available are consistent with the notion of some protection of OC in current but not in former users, although possible effects of diagnostic and selection bias should be considered. Published data on the relationship between fibroids and OC appear too scattered to allow a precise quantification of risk. In any case, any relationship is moderate and, hence, of limited clinical and public health relevance. The data on OC and benign gynecologic conditions are reassuring in their absence of any consistent excess risk.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral Endometriosis Leiomyoma Ovarian Cysts Contraceptives, Oral Endometriosis Endometriosis Female Humans Leiomyoma Leiomyoma Ovarian Cysts Ovarian Cysts Prevalence Risk Factors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (40)

Cited by (14)

Source provenance

europepmc
last seen: 2026-08-01T06:07:04.264727+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0 · commercial use OK